期刊文献+

卡维地洛与美托洛尔治疗扩张型心肌病合并心力衰竭的疗效比较 被引量:8

Comparison of the effect of carvedilol and metoprolol in the treatment of dilated cardiomyopathy patientswith heart failure
原文传递
导出
摘要 目的比较卡维地洛与美托洛尔治疗扩张型心肌病(DCM)合并心力衰竭的临床疗效。方法将90例DCM合并心力衰竭患者按照治疗方法不同分为观察组和对照组,各45例。两组均采用利尿、扩血管、强心等药物治疗,对照组加用美托洛尔,观察组加用卡维地洛。连续治疗4-6个月。治疗前后检测和比较两组患者左室射廊分数(LVEF)、左室收缩末内径(LVESVI)、左室舒张内径(LVEDVI)、左心室短轴缩短率(FS)、最大峰值血流速度(hCFV)、冠状动脉啦流储备(GFR)、觑清内皮素(ET)及一氧化氮(N0)含量。结暴观察组治疗后LVEF、LVEDVI、LVESVI、FS、hCFV、CFR、ET、NO分别为(44.0±3.4)ml/m^2、(45.2±6.9)mm、(20.9±5.4)mm、(30.4±5.3)、(78,2±31,6)cm/s、(3.12±0.36)、(52,2±5.6)ng/L、(5.2±0.67)μmol/L,均优于对照组治疗后的(37.9±3.5)ml/m^2、(51,1±7,6)mm、(20,7±6.3)mm、(25.2±7.3)、(70.5±31.8)cm/s、(2.85±0.23)、(63.5±1.8)ng/L、(2,55±0,33)μmol/L(t=8.386、-3.856、-4.487、3.867、-1.152、-4.239、12.887、-23.802,均P〈0.05)。结论 卡维地洛是治疗DCM合并心理衰竭的有效药物,能改善患者心功能、冠脉癣流储备能力及内废功能,效果满意,值得在临床推广。 Objective To compare the clinical officacy of oarwdilol and metoprolol in the treatment of dilat-ed cardiomyopathy patients with heart failure (DCM), Methods According to the different treatment method, 90 DCM patients with heart failure patients were divided into the observation group and the control group,45 cases in each group. Both groups were given a diuretic, vasodilator, cardiao and other drug treatment, and the control group were added with metoprolol,and the observation group were added with carvodilol. The treatment lasted 4 to 6 months. Before and after treatment, the levels of left ventricular ejection fraction(LVEF) ,left ventricular end-systolic diameter ( LVESVI), left ventricular diastolic diameter (LVEDVI), left ventricular fractional shorteningrate ( FS), largest peak velocity ( hCFV), coronary flow reserve ( CFR), simultaneous deteotion of serum levels of endothelin (ET) and nitric oxide(NO) content were observed and compared between the two groups. Results After the treatment, the levels of LVEF, LVESVI, LVEDVI, FS, hCFV, CFR, ET, NO of the observation group were ( 44.0 ±3.4 ) ml/m2, ( 45.2 ± 6.9)mm,(20.9±5.4)mm,(30.4 ±5.3), (78, 2±31. 6) cm/s, (3, 12 ±0.36), (52.2 ±5.6)ng/L, (5.2 ± 0.67) ±mol/L,respectively, which were better than those of those control group [ (37.9±3.5 )ml/m2, (51. 1 ± 7.6)mm,(20.7 ±6.3) mm,(25.2 ±7.3),(70.5 ±31,8)cm/s, (2.85 ±0.23),(63.5 ± 1.8)ng/L, (2.55 ± 0. 33)μmol/L] (t = 8. 386, - 3. 856, - 4. 487,3,867,-1. 152, -4. 239,12. 887, - 23. 802, all P 〈 0. 05 ). Conclusion Carvedilol is an effective drug for the treatment of DCM consolidated psychological failure, which can improve heart function and coronary flow reserve capacity and endothelial function in patients, which is worth in the clinical with satisfactory results.Cardiomyopathy, dilated ; Heart failure, congestive; Carvedilol ; Metoprolol
作者 肖春丽
出处 《中国基层医药》 CAS 2013年第18期2737-2739,共3页 Chinese Journal of Primary Medicine and Pharmacy
关键词 心肌病 扩张型 心力衰竭 充血性 卡维地洛 美托洛尔 Cardiomyopathy, dilated Heart failure, congestive Carvedilol Metoprolol
  • 相关文献

参考文献13

二级参考文献56

  • 1李德之.心力衰竭时β-阻滞剂应用的原则与经验[J].中国实用内科杂志,1994,14(2):75-76. 被引量:70
  • 2邱忠霞,马贺军,王涤非.复方丹参滴丸联合曲美他嗪治疗老年不稳定心绞痛疗效观察[J].中国中西医结合杂志,2005,25(9):787-789. 被引量:19
  • 3朱红俊,龚少愚,邹逊,魏慧渊,陆曙.心力衰竭病因对血浆BNP水平的影响[J].临床荟萃,2007,22(1):27-28. 被引量:25
  • 4Bots ML,Remme WJ, Luscher TF, et al. ACE inhibition and endothelial function: main findings of PERFECT, a sub-study of the EUROPA trail[J]. Cardiovasc Drugs Ther, 2007,21 (4) : 269-279. 被引量:1
  • 5Hunt SA, American College of Cardiology, American Heart Association Task Force on Practice Guidelines. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) [J]. J Am Coll Cardiol,2005,46(6) :e1-82. 被引量:1
  • 6Anonymous. The Cardiac Insufficiency Bisoprolol Study Ⅱ (CIBIS- Ⅱ ) : a randomised trial[J]. Lancet, 1999,353(9146) : 9- 13. 被引量:1
  • 7Wikstrand J, Hjalmarson A, Waagstein F, et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERITHF)[J]. J Am Coll Cardiol. 2002,40(3),491- 498. 被引量:1
  • 8Fowler MB. Carvedilol prospective randomized cumulative survival (COPERNICUS) trial: carvedilol in severe heart failure[J]. Am J Cardiol,2004,93(9A) :35B-39B. 被引量:1
  • 9Cleland JG,Cbarleowortb A,Lubsen J, et al. A comparison of the effects of carvedilol and metoprolol on well-being, morbidity,and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trail(COMET)[J]. J Am Coll Cardiol,2006,47(8): 1603-1611. 被引量:1
  • 10Tolg R,Witt M,Schwarz B,et al. Comparison of carvedilol and metoprolol in patients with acute myocardial infarction undergoing primary coronary intervention--the PASSAT Study [J]. Clin Res Cardiol,2006,95(1);31-41. 被引量:1

共引文献2522

同被引文献42

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部